Everything You Need to Know About the 2024 RSV Season
Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...
LasVegasOptic.com1 天
RSV vaccinations recommended for vulnerable populations
Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...
BioPharma Dive1 天
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
BioSpace1 天
CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
FiercePharma2 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
pulmonologyadvisor2 天
RSV Vaccine Abrysvo Approved for Adults Aged 18 to 59 at Increased Risk
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Pharmabiz2 天
Pfizer receives US FDA approval for its RSV vaccine Abrysvo for adults aged 18 to 59 at ...
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...
biopharma-reporter2 天
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
腾讯网3 天
辉瑞(PFE.US)RSV疫苗获FDA批准用于18-59岁年龄段人群接种
智通财经获悉，美国食品药品监督管理局(FDA)已批准辉瑞公司(PFE.US)的呼吸道合胞病毒(RSV)疫苗Abrysvo用于18至59岁下呼吸道疾病风险增加的人群。这些疾病包括肥胖、糖尿病、慢性阻塞性肺病、心力衰竭、慢性肾病和哮喘。扩大批准是基于3期 ...
腾讯网3 天
首款！辉瑞疫苗再获FDA批准
▎药明康德内容团队编辑日前，辉瑞（Pfizer）宣布美国FDA已批准其呼吸道合胞病毒（RSV）疫苗Abrysvo（RSVpreF），用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病（LRTD）。此前，该疫苗已获批用于60岁及以上的成人群体。根 ...
McKnight's Long-Term Care News3 天
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
每日经济新闻 on MSN3 天
医药早参｜诺泰生物及实际控制人之一被证监会立案
｜ 2024年10月24日 星期四 ｜ NO.1 诺泰生物及实际控制人之一被证监会立案 ...